Skip to main content

Follow us

Home

Search

the Gateway to Research in Oklahoma

  • Researchers
  • Providers
  • Patients
  • About GRO

Gateway to Research in Oklahoma


Oklahoma Shared Clinical and Translational Resources U54 GM104938

Researchers

imgResearchers

The GRO: Researcher Portal provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in Oklahoma.

Providers

imgProviders

The GRO: Provider Portal assists medical providers to identify clinical research opportunities in Oklahoma, tools for patient education, and evidence-based resources to improve patient care.

Patients

imgPatients

The GRO: Patient Portal can help patients and families to learn more about clinical and translational research and to connect with opportunities to participate in research opportunities in your communities.

Oklahoma Research Highlights

Reducing ED Boarding Time as the Key to Minimizing Admission Delays: A Quality Improvement Initiative

1 month 3 weeks ago
No abstract
Gina Moon

A Paradoxical Increase in Ventricular Arrhythmia After a Left Stellate Ganglion Block: A Case Report

1 month 3 weeks ago
Ultrasound-guided left-sided or bilateral stellate ganglion block (SGB) has emerged as an effective bedside intervention for malignant ventricular arrhythmias (VA) refractory to conventional therapies, with demonstrated safety and efficacy in multiple studies. We report a medically complex patient with presumed genotype-negative Long QT Syndrome (LQTS) who experienced a sudden, transient increase in arrhythmic events shortly after an uncomplicated left-sided ultrasound-guided SGB. To our...
Sharon M Bouvette

Activity of Nonhallucinogenic Ibogalogs on Chemotherapy-Induced Peripheral Neuropathic Pain in Mice

1 month 3 weeks ago
In this study, we examined the effects of ibogaminalog (DM506), a nonhallucinogenic analog of ibogamine, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) induced by paclitaxel. We also assessed the effects of tabernanthalog (TBG) and investigated the potential role of serotonin receptor subtype 2A (5-HT(2A)R) for both compounds. DM506 and TBG demonstrated antinociceptive activity in the CIPN model. DM506 produced a more prolonged effect, lasting between 10 and 14 days, with...
Jason Younkin

Special collection on advancing pharmacotherapy for age-related diseases: Bridging treatment gaps and innovations for the aging population

1 month 3 weeks ago
No abstract
Yagna P R Jarajapu

Use of extracorporeal membrane oxygenation in neonates with congenital anomalies of the kidney and urinary tract: a multicenter survey of current practices across CHNC and Pedi-ECMO centers

1 month 3 weeks ago
CONCLUSIONS: Variability among providers and institutes underscores the need for consensus-based guidelines to optimize decision-making and outcomes.
Syed Ahmed

Pagination

  • Previous page ‹ Previous
  • Page 105
  • Next page Next ›
Subscribe to

octsi logo

1000 N. Lincoln Blvd, Suite 2100, Oklahoma City, OK 73104
Copyright © 2021 The Board of Regents of the University of Oklahoma, All Rights Reserved.

About GRO

News
Publications
FAQ

Terms of Use

Privacy Policy
Accessibility

Contact

info email
info phone
Copyright © 2026. All rights reserved. Designed By Zymphonies